September 2013 media hits

Public Citizen is mentioned, or its experts quoted, every day in print and broadcast media around the world. Below are links to some of the recent stories in which we have appeared.

Drug Companies’ Dirty New Markets

10/1/2013
Soren Drier: Drug Companies’ Dirty New Markets by Cesar Chelala - According to a report by the Public Citizen’s Health Research Group in Washington, D.C., four companies (GlaxoSmithKline, Pfizer, Eli Lilly, and Schering-Plough) accounted for more than half of all financial penalties imposed over drug companies in the last two decades.  

The Most Sinister Corporate Power Grab Yet

10/1/2013
Disinformation: The Most Sinister Corporate Power Grab Yet by Diane Petryk-Bloom - “Fast Track” would have Congress voting up or down on the massive document without any power to discuss or amend any of it. This is an arcane procedure devised by Richard Nixon, according to Public Citizen’s Lori Wallach, “but that was when trade negotiations covered only real trade stuff.”  

Shut It Down

10/1/2013
Green Goddess: Shut It Down - If one believes that in fact over 100K of medical errors are made annually then one perusal of that report should ameliorate any belief that we have a crisis on hand with regards to medical malpractice. Public Citizen did a study almost a decade ago and the numbers have not changed. But again when the idea of depth is that what you can dig with a plastic spoon it is easy to not go very deep.  

Patents Against People: How Drug Companies Price Patients out of Survival

10/1/2013
Dissent: Patents Against People: How Drug Companies Price Patients out of Survival by Michelle Chen - "We’re concerned that the TPP is, in part, a closed-door hemispheric rule-making against public health,” says Peter Maybarduk, director of Public Citizen’s Global Access to Medicine program. The Obama administration’s free trade agenda, he adds, actually threatens to unravel some of the hard-fought gains in access to medical treatment that were initiated under the Bush administration’s international HIV/AIDS initiatives.  

Congress Moves Closer on Compounding Bill

10/1/2013
MedPage Today: Congress Moves Closer on Compounding Bill by David Pittman - "The FDA can do more to prevent another NECC-like disaster by being more aggressive in enforcing existing law," Michael Carome, MD, director of Public Citizen's Health Research Group, said in a statement. "Congress also can help by passing a law that clarifies the line between drug manufacturing and compounding, and does other important things like requiring warning labels for compounded drugs, and giving the FDA authority to inspect pharmacy records.  

U.S., EU trade heads talk regulatory differences

10/1/2013
Politico: U.S., EU trade heads talk regulatory differences by Eric Bradner - “The core premise of these studies is the unproven business mantra that rolling back Wall Street reforms, food health standards and medicine safety regulations will somehow deliver economic gains to us all,” said the Washington-based group Public Citizen, which opposes the trade pacts being negotiated by President Barack Obama’s administration. “The main contribution of the recent flurry of studies is the addition of extra gloss and fancy printing to the old, debunked assumption that such an assault on consumers, workers and the environment would have zero costs.”   

Regulators Have Called Off the Dogs, but Concern Over Januvia Lingers

9/5/2013
Regulators Have Called Off the Dogs, but Concern Over Januvia Lingers - Regulators and the pharmaceutical industry have dismissed a study that noted consumer advocacy group Public Citizen referenced as “brilliantly-designed and executed.” Drs. Alexandra Butler and Peter Butler, of whom we have referenced before, undertook the study with their colleagues in concert with UCLA in California and the University of Florida.

What you need to know about acetaminophen

9/3/2013
What you need to know about acetaminophen - Acetaminophen is also the top cause of acute liver failure in the U.S. says Sidney Wolfe, M.D., a former member of the FDA’s Drug Safety and Risk Management Committee. Tylenol, in particular, is currently cited in more than 85 personal injury lawsuits for liver injuries and deaths related to its drugs.

U.S. Weighs Informed Consent Rules in Wake of Infant Study Controversy

9/3/2013
U.S. Weighs Informed Consent Rules in Wake of Infant Study Controversy - The nonprofit watchdog group Public Citizen circulated OHRP’s letter to reporters, drawing widespread media attention. OHRP charged researchers with failing to provide sufficient warning to parents of the 1300 babies in the study. It said researchers should have told parents about concerns that the high-oxygen saturation group had a potentially greater risk of eye disease, while babies in the lower group might be more likely to die or suffer developmental delays. Both concerns proved true at statistically significant levels.

Will Improvements To Medical Examining Board Be Enough?

9/3/2013
Will Improvements To Medical Examining Board Be Enough? - In 2012, Public Citizen, a consumer advocacy group, ranked Connecticut fifth-lowest among states in taking serious disciplinary actions against physicians between 2009 and 2011.

For Immediate Release on Tuesday, September 3

9/3/2013
For Immediate Release on Tuesday, September 3 - Level playing field for union election U.S. District Judge Colleen Kollar-Kotelly ruled that challengers seeking to unseat incumbent officers of the American Postal Workers Union are entitled to use the union’s email database to send campaign literature to voters. The decision interprets a provision of the Labor-Management Reporting and Disclosure Act that provides candidates a right to distribute campaign literature at his or her own expense. Public Citizen brought the suit on behalf of three APWU candidates.

Differences on display on US informed consent rules

9/3/2013
Differences on display on US informed consent rules - After OHRP criticized the study’s consent forms in March, a string of reaction followed from the highest research echelons. They included this commentary in the New England Journal of Medicine by NIH director Francis Collins and his policy deputy, Kathy Hudson. Most of the responses defended the trial and the forms, arguing that the babies were put at no additional risk. But a vocal minority of physicians and bioethicists and the advocacy group Public Citizen have loudly disagreed. So did this Nature editorial, published last week.

Regulation Nation: Obama rule-making seen as deeply flawed

9/3/2013
Regulation Nation: Obama rule-making seen as deeply flawed - Amit Narang, a regulatory policy advocate with the pro-regulation Public Citizen, said that the outside commission would likely just be a way to kill old rules without strengthening current ones.